2Peerlinck K,De Lepeleire I,Goldberg M,et al.A selective nonpeptide platelet glycoprotein Ⅱb/Ⅲa antagonist,it active in man[J].Circulation,1993,88(4):1512.
3Coller BS,Peerschke EI,Scudder LE,et al.A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces a thrombosthenic like state in normal platelets and binds to glycoproteins Ⅱb and/or Ⅲa[J].J Clin Invest,1983,72:325.
4Randomised placebo controlled and balloon angioplasty controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-Ⅱb/Ⅲa blockade.The EPISTENT Investigators.Evaluation of platelet Ⅱb/Ⅲa inhibitor for stenting[J].Lancet,1998,352:87.
5The EPIC Investigators.Use of monoclonal antibody directed against the platelet glycoprotein Ⅱb/Ⅲa receptor in high-risk coronary angioplasty[J].N Engl J Med,1994,330(14):956.
6Simoons ML.GUSTO Ⅳ-ACS Investigators.Effect of Glycoprotein Ⅱb/Ⅲa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation:the GUSTO Ⅳ-ACS randomised trial[J].Lancet,2001,357 (9272):1915.
7Scarborough RM,Naughton MA,Teng W,et al.Design of potent and specific integrin antagonists.Peptide antagonists with high specificity for glycoprotein Ⅱb/Ⅲa[J].J Biol Chem,1993,268:1066.
8Jennings L,Tardiff B,Philips D,et al.Comparison of recept or occupancy and platelet aggregation response of epifibatide administered intravenously in patients with unstable angina or non Q wave myocardial infarction[J].J Am Coll Cardiol,1998,31(2A):93A.
9Mahaffey KW,Harrington RA,Simoons ML,et al.Stroke in patients with acute coronary syndromes:incidence and outcomes in the platelet glycoprotein Ⅱb/Ⅲa in unstable angina.Receptor suppression using integrilin therapy (PURSUIT) trial.The PURSUIT Investigators[J].Circulation,1999,99 (18):2371.
10Egberston MS,Chang CT,Duggan ME,et al.Nonrrpeptide fibrinogen receptor antagonist 2.Optimization of a tyrosine template a mimic for Arg-Gly -Asp[J].J Med Chem,1994,37:2537.
2Ragaseema VM,Unnikrishnan S,KalliyanaKrishnan V. The antithrombotic and antimicrobial properties of PEG-protected silver nanoparticle coated surfaces[J].Biomaterials,2012,(11):3083-3092.
3Ales Doliska,Stefan Willfoer,Simona Strnad. Antithrombotic properties of sulfated wood-derived galactoglucomannans[J].Holzforschung,2012,(02):149-154.
